Focusound™️ Announces Upcoming Launch of the See-Thru Glass 20-02-2023, 22:04

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

C.K. McWhorter Announces Next Steps Into Sustainable Luxury and Global Philanthropic Impact 8-02-2024, 02:23